ARS Pharmaceuticals (SPRY) Competitors $11.18 -0.14 (-1.24%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SPRY vs. ACLX, ADMA, RARE, APLS, BHVN, IMVT, RNA, SRRK, OGN, and PTCTShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Biohaven (BHVN), Immunovant (IMVT), Avidity Biosciences (RNA), Scholar Rock (SRRK), Organon & Co. (OGN), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Immunovant Avidity Biosciences Scholar Rock Organon & Co. PTC Therapeutics Arcellx (NASDAQ:ACLX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk. Does the media refer more to ACLX or SPRY? In the previous week, Arcellx and Arcellx both had 6 articles in the media. Arcellx's average media sentiment score of 1.06 beat ARS Pharmaceuticals' score of 0.50 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, ACLX or SPRY? ARS Pharmaceuticals has lower revenue, but higher earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$155.82M26.22-$70.69M-$0.71-106.39ARS Pharmaceuticals$2.57M423.10-$54.37M-$0.51-21.92 Do analysts prefer ACLX or SPRY? Arcellx currently has a consensus price target of $105.93, indicating a potential upside of 40.23%. ARS Pharmaceuticals has a consensus price target of $24.00, indicating a potential upside of 114.67%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has more volatility and risk, ACLX or SPRY? Arcellx has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Does the MarketBeat Community prefer ACLX or SPRY? Arcellx received 49 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. Likewise, 82.93% of users gave Arcellx an outperform vote while only 82.61% of users gave ARS Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArcellxOutperform Votes6882.93% Underperform Votes1417.07%ARS PharmaceuticalsOutperform Votes1982.61% Underperform Votes417.39% Do institutionals and insiders hold more shares of ACLX or SPRY? 96.0% of Arcellx shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 6.2% of Arcellx shares are held by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ACLX or SPRY more profitable? ARS Pharmaceuticals has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-25.94% -8.28% -5.21% ARS Pharmaceuticals N/A -22.56%-21.82% SummaryARS Pharmaceuticals beats Arcellx on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-21.9210.5991.3417.19Price / Sales423.10195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book4.665.104.794.78Net Income-$54.37M$151.51M$120.07M$225.60M7 Day Performance-6.05%-2.15%-1.89%-1.24%1 Month Performance-16.66%-3.14%11.45%3.36%1 Year Performance119.22%11.50%30.61%16.58% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals3.1441 of 5 stars$11.18-1.2%$24.00+114.7%+121.8%$1.09B$2.57M-21.9290Insider TradeNews CoverageHigh Trading VolumeACLXArcellx3.1377 of 5 stars$85.05+1.5%$105.93+24.5%+49.1%$4.60B$155.82M-118.03130Positive NewsADMAADMA Biologics3.7751 of 5 stars$19.13+2.9%$21.25+11.1%+325.4%$4.52B$382.81M68.32530RAREUltragenyx Pharmaceutical4.4444 of 5 stars$46.29+1.1%$87.46+88.9%-2.6%$4.27B$434.25M-7.081,276Analyst ForecastNews CoverageAPLSApellis Pharmaceuticals4.563 of 5 stars$33.34+0.5%$49.94+49.8%-39.6%$4.15B$396.59M-16.35702Analyst DowngradePositive NewsBHVNBiohaven3.7186 of 5 stars$40.23+4.6%$63.00+56.6%-4.4%$4.07B$462.51M-4.11239Analyst ForecastIMVTImmunovant1.4556 of 5 stars$27.63+5.1%$47.89+73.3%-28.5%$4.06BN/A-11.84120Analyst ForecastNews CoverageRNAAvidity Biosciences2.1828 of 5 stars$33.85+4.2%$63.60+87.9%+278.8%$4.04B$10.12M-11.28190Analyst ForecastInsider TradeAnalyst RevisionNews CoverageSRRKScholar Rock3.8794 of 5 stars$43.13+2.7%$40.43-6.3%+152.3%$4.04B$33.19M-18.35140Positive NewsOGNOrganon & Co.4.8019 of 5 stars$14.72-3.8%$21.33+44.9%+10.9%$3.79B$6.26B2.9110,000PTCTPTC Therapeutics3.6566 of 5 stars$47.77+3.0%$54.08+13.2%+71.0%$3.68B$937.82M-7.811,410Analyst DowngradePositive News Related Companies and Tools Related Companies ACLX Competitors ADMA Competitors RARE Competitors APLS Competitors BHVN Competitors IMVT Competitors RNA Competitors SRRK Competitors OGN Competitors PTCT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRY Stock Alerts